SuperworthZevra Therapeutics PE ratio ZVRA
Share price divided by earnings per share over the last twelve months, since 2014.
- Today, Oct 23, 2026
- 10.5×
- Earnings per share, 12 months
- $0.93
- to Jun 30, 2026
- Share price
- $9.81
- Oct 23, 2026
- Peer median
- 12.8×
Zevra Therapeutics' PE ratio is 10.5× as of Oct 23, 2026: a share price of $9.81 against $0.93 of earnings per share over the last twelve months.
It earned $0.93 a share over the twelve months to Jun 30, 2026, against a share price of $9.81 on Oct 23, 2026. It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.
The median for 10 large drugmakers of a similar size is 12.8×.
Earnings per share over time
A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.34 | n/a |
| FY2024 | n/a | n/a |
| FY2021 | −$3.03 | n/a |
| FY2020 | −$3.46 | n/a |
| FY2019 | −$14.56 | n/a |
| FY2018 | −$61.12 | n/a |
| FY2017 | −$47.20 | n/a |
| FY2016 | −$18.72 | n/a |
| FY2015 | −$100.32 | n/a |
| FY2014 | −$164.32 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.14 | −88% | $0.93 | |
| Q1 FY26 | $0.60 | n/a | $2.00 | |
| Q4 FY25 | $0.20 | n/a | $1.34 | |
| Q3 FY25 | −$0.01 | n/a | $0.47 | |
| Q2 FY25 | $1.21 | n/a | −$0.21 | |
| Q1 FY25 | −$0.06 | n/a | −$1.90 | |
| Q4 FY24 | −$0.67 | n/a | n/a | |
| Q3 FY24 | −$0.69 | n/a | n/a | |
| Q2 FY24 | −$0.48 | n/a | n/a | |
| Q4 FY21 | −$0.08 | n/a | −$3.03 | |
| Q3 FY21 | −$0.06 | n/a | −$4.02 | |
| Q2 FY21 | −$0.40 | −290% | −$4.64 |
Against its peers
Companies in Drug Manufacturers - General nearest Zevra Therapeutics' size, closest first, today.
| Company | PE ratio |
|---|---|
| ZVRAZevra Therapeutics | 10.5× |
| IRWDIronwood Pharmaceuticals | 4.5× |
| PBYIPuma Biotechnology | 21.2× |
| CRMDCorMedix | 3.7× |
| ARVNArvinas | 45.6× |
| COLLCollegium Pharmaceutical | 18.5× |
| ABUSArbutus Biopharma | 5.4× |
| AMPHAmphastar Pharmaceuticals | 14.8× |
| OMEROmeros | 10.9× |
| PCRXPacira BioSciences | 104× |
| ANABAnaptysbio | 10.7× |
| Peer median | 12.8× |
Where Zevra Therapeutics ranks
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Zevra Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.